Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER)
-
Published:2022-01
Issue:
Volume:161
Page:26-37
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
Albanell J., Martínez M.T., Ramos M., O'Connor M., de la Cruz-Merino L., Santaballa A., Martínez-Jañez N., Moreno F., Fernández I., Alarcón J., Virizuela J.A., de la Haba-Rodríguez J., Sánchez-Rovira P., González-Cortijo L., Margelí M., Sánchez-Muñoz A., Antón A., Casas M., Bezares S.ORCID, Rojo F.
Subject
Cancer Research,Oncology
Reference23 articles.
1. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future;Spring;Lancet,2020 2. Palbociclib and letrozole in advanced breast cancer;Finn;N Engl J Med,2016 3. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer;Hortobagyi;Ann Oncol,2018 4. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer;Johnston;NPJ Breast Cancer,2019 5. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial;Tripathy;Lancet Oncol,2018
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|